NL-OMON46128已完成2 期
A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients. - CCLR325X2202
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Written informed consent must be obtained before any assessment is performed;
- •- Able to communicate well with the investigator, to understand and comply with the requirements of the study;
- •- Male and female patients >18 years of age.
- •- Patients must weigh between 50kg and 140 kg to participate in the study;
- •- Patients with a cardiac ejection fraction of * 45% as assessed within the last 6 months;
- •- For PA catheter cohorts, patients who are planned to have a clinically indicated pulmonary artery catheter in place prior to randomization;
- •- In the opinion of the investigator, heart failure patients who will not require a change in their dose of ACE, ARB, *-blocker, mineralocorticoid receptor antagonist, or diuretic for 24 hours after randomization
- •- At baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least five minutes
排除标准
- •- Presence of impaired renal function as indicated by clinically significant abnormal creatinine values (eGFR< 30 ml/min/1.73m2 calculated using the MDRD equation)
- •- Patients with values of AST or ALT>100 U/L measured within the last 3 months before randomization
- •- Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV). positive Hepatitis B surface antigen (HBsAg) test excludes a patient. Patients with a positive Hepatitis C antibody test should have HCV RNA levels measured. Patients with positive (detectable) HCV RNA should be excluded.
- •- Patients with a history of chronic hepatitis of any non-cardiac etiology.
- •- History of any active, clinically significant cardiac tachyarrhythmia, such as recurrent atrial fibrillation with rapid ventricular response within the last year. Anticoagulation for patients with atrial fibrillation should be managed per usual clinical practice for patients undergoing right heart catheterization.
- •- Patients who have received an intravenous infusion of a cardiac inotrope (e.g.,dobutamine or milrinone) in the last 24 hours prior to randomization.
- •- For PA catheter cohorts, patients with a pulmonary capillary wedge pressure of >10 mm Hg at baseline.
- •- Patients with any significant change in their dose of their ACE, ARB, mineralocorticoid receptor antagonist, diuretic or *-blocker within the last 12 hours.
- •- Patients with minor changes in their heart failure regimen may be eligible if deemed clinically stable by both the investigator and sponsor.
- •- Patients with known significant valvular heart disease, as indicated by the following:
- •- Severe aortic stenosis (Aortic Valve Area >1.0 cm2 or peak gradient 50 mmHg as determined by echocardiography)
- •- Severe mitral stenosis
- •- Patients with history of acute coronary syndrome within the last 60 days as determined by both clinical and enzymatic criteria.
研究者
相似试验
进行中（未招募）
1 期
A Study of CLR325 in Chronic Stable Heart Failure Patients.Stable Heart FailureMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-001387-12-BEovartis Pharma Services AG40
进行中（未招募）
1 期
A Study of CLR325 in Chronic Stable Heart Failure Patients.EUCTR2016-001387-12-DEovartis Pharma Services AG40
进行中（未招募）
1 期
A Study of CLR325 in Chronic Stable Heart Failure Patients.EUCTR2016-001387-12-NLovartis Pharma Services AG40
进行中（未招募）
1 期
A study to find out the safety, tolerability and interaction of RO7268489 with body (including the effect of itraconazole on RO7268489) and also what the body does to RO7268489 after oral intake by healthy participantsISRCTN14119236F. Hoffmann-La Roche Ltd68
招募中
2 期
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosisidiopathic pulmonary fibrosisNL-OMON55928ovartis6